Cell-based Delivery Systems for Antiangiogenic Therapy

Biotechnology and Genetic Engineering Reviews

Volumn 20, Issue 1, 2003, Pages 183-198

  Machluf, Marcelle ^a   Carroll, Rona S ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-ANGIOGENIC THERAPY; CELL-BASED; DELIVERY SYSTEMS;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER THERAPY; CELL BASED GENE THERAPY; CELL ENCAPSULATION; CELL ENCAPSULATION FOR ANTIANGIOGENIC TUMOR THERAPY; GENE THERAPY; GENETIC ENGINEERING; REVIEW;

EID: 1242291894     PISSN: 02648725     EISSN: 20465556     Source Type: Journal    
DOI: 10.1080/02648725.2003.10648043     Document Type: Article

References (91)

1. AEBSCHER, P., POCHON, N. A., Heyd, N.B. et al. (1996a). Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Human Gene Therapy 7, 851-860.
2. Aebischer, P., SCHLUEP, M., Deglon, N. et al. (1996b). Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Medicine 2,696-699.
3. ALGIRE, G.H. (1943). An adaption of the chamber technique to the mouse. National Cancer Institute Journal 4, 1-11.
4. ARENBERG, D.A., POLVERINI, P.J., Kunkel, S.L. et al. (1997). In vitro and in vivo systems to assess role of CXC chemokines in regulation of angiogenesis. Methods in Enzymology 288, 190-220.
5. Bello, L., Lucini, V., Giussani, C. et al. (2001). In vitro and in vivo inhibition of angiogenesis, proliferation and migration by PEX, a MMP-2 fragment purified from human glioma cells. Cancer Research 61, 8730-8736.
6. BENI-SHAY, Z. and SHARON, S. (1977). Macrophages and/or fibroblasts in hematopoietic diffusion chamber cultures. Israel Journal of Medical Sciences 13(4), 385-393.
7. Brooks, P.C., Sillettf, T.L., Schalscha, M. et al. (1998). Disruption of angiogenesis by PEX. a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92, 391-400.
8. Cima, L.G., INGBER, D., VACANTI, J.P. et al. (1991). Hepatocyte culture on biodegradable polymeric substrates. Biotechnology and Bioengineering 38, 145.
9. CIRONE, P., BOURGEOIS, J.M., AUSTIN, R.C. and CHANG, P.L. (2002). A novel approach to tumor suppression with microencapsulated recombinant cells. Human Gene Therapy 13, 1157-1166.
10. Dai, Y., ROMAN, M., NAVIAUX, R.K. and VERMA, I.M. (1992). Gene therapy via primary myoblasts: long-term expression of rat glial factor IX protein following transplantation in vivo. Proceedings of the National Academy of Sciences of the United States of America 89, 10892-10895.
11. Dawson, D.W., Volpert, O.V., Gillis, P. et al. (1999). Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245-248.
12. Deglon, N., Heyd, B. and Tan, S. A. (1996). Central nervous system delivery of recombinant ciliary neurotrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Human Gene Therapy 7, 2135-2146.
13. DIAS, S., HATTORI, K., HEISSIG, B. et al. (2001). Inhibition of both paracrine and autocrine VEGF/VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias. Proceedings of the National Academy of Sciences of the United States of America 98,10857-10862.
14. Ding, I., Sun, J.Z., FENTON, B. et al. (2001). Intra-tumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. Cancer Research 61,526-531.
15. Eder, J.P., Supko, J.G., Clark, J.W. et al. (2002). Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. Journal of Clinical Oncology 20, 3773-3784.
16. Emerich, D.F., McDermott, P.E., Krueger, P.M. et al. (1994). Intrastriatal implants of polymer-encapsulated PC 12 cells: pro-effects on motor function in aged rats. Progress in Neuro-psychopharmacology and Biological Psychiatry 18, 935-946.
17. Emerich, D.F., Plone, M., Francis, J. et al. (1996). Alleviation of behavioral deficits in aged rodents following implantation of encapsulated GDNF-producing fibroblasts. Brain Research 736, 99-110.
18. EMERICH, D.F., Cain, C.K., Greco, C. et al. (1997a). Cellular delivery of human CNTF prevents motor and cognitive dysfunction in a rodent model of Huntington’s disease. Cell Transplant 6, 249-266.
19. Emerich, D.F., Winn, S.R., Hantraye, P.M. et al. (1997b). Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey mode! of Huntington’s disease. Nature 386, 395-399.
20. Ferber, D. (2001). Gene therapy: safer and virus-free? Science 294, 1638-1642.
21. FOLKMAN, J. (1971). Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 285,1182-1186.
22. Folkman, J. (1992). The role of angiogenesis in tumor growth. Seminars in Cancer Biology 3, 65-71.
23. FOLKMAN, J, (1998). Antiangiogenic gene therapy. Proceedings of the National Academy of Sciences of the United States of America 95,9064-9066.
24. Folkman, J. and D’Amore, P.A. (1996). Blood vessel formation: what is its molecular basis? Cell 87, 1153-1155.
25. FOLKMAN, J. and SHING, Y. (1992). Angiogenesis. Journal of Biological Chemistry 267, 10931-10934.
26. Hagedorn, M. and BikfaLvi, A. (2000). Target molecules for antiangiogenic therapy: from basic research to clinical trials. Critical Reviews in Oncology-Hematology 34, 89-110.
27. Hammang, J.P., Emerich, D.F., Winn, S.R. et al. (1995). Delivery of neurotrophic factors to the CNS using encapsulated cells: developing treatments for neurodegenerative diseases. Cell Transplant 4, S27-28.
28. HANAHAN, D. and FOLKMAN, J, (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
29. Harsh, G.R., Deisboeck, T.S. and Louis, D.N. (2000). Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. Journal of Neurosurgery 92, 804-811.
30. Herbst, R.S., Hess, K.R., Tran, H.T, ET AL. (2002). Phase I study of recombinant human endostatin in patients with advanced solid tumors. Journal of Clinical Oncology, 20,3773-3784.
31. HIRSCHI, K.K., SKALAK, T.C., PEIRCE, S.M. and LITTLE, C.D. (2002). Vascular assembly in natural and engineered tissues. Annals ofthe New York Academy of Sciences 961,223-242.
32. Hoffman, D., Breakefield, X.O., Short, M.P. et al. (1993). Transplantation of a polymer-encapsulated cell line genetically engineered to release NGF. Experimental Neurology 122, 100-106.
33. Hortelano, G., Al-Hendy, A., Ofosu, F.A. and Chang, P.L. (1996). Delivery of human factor IX in mice by encapsulated recombinant myoblasts: a novel approach towards allogeneic gene therapy of hemophilia B. Blood 87,5095-5103.
34. JAIN, R.K., SCHLENGER, K., HÖCKEL, M. and YUAN, F. (1997). Quantitative angiogenesis assays: progress and problems. Nature Medicine 3, 1203-1208.
35. JOKI, T., MACHLUF, m., Atala, A. et al. (2001). Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nature Biotechnology 19,35-39.
36. JOUAN, V., Canron, X., Alemany, M. et al. (1999). Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action. Blood 94, 984-993.
37. Kamphaus, G.D., Colorado, P.C., Panka, D.J, ET AL. (2000). Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. Journal ofBioloeical Chemistry 275. 1209-1215.
38. Kaushal, S., AMIEL, G.E., Guleserian, K.J. et al. (2001). Functional small-diameter neovessels created using endothelial progenitor cells expanded ex vivo. Nature Medicine 7, 1035-1040.
39. Kim, K.J., Li, B., Winer, J. et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 362, 841-844.
40. Kisker, O., BECKER, C.M., PROX, D. et al. (2001). Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Research 61, 7669-7674.
41. KUO, C.J., Farnebo, F., Yu, E.Y. et al. (2001a). Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer. Proceedings of the National Academy of Sciences of the United States of America 98,4605-4610.
42. Kuo, C.J., FARNEBO, F., YU, E.Y. et al. (2001b). Comparative evaluation of the antilumor activity of antiangiogenic proteins delivered by gene transfer. Proceedings ofthe National Academy of Sciences of the United States ofAmerica 98,4605-4610.
43. Lacy, P.E. (1995). Treating diabetes with transplanted cells. Scientific American 273,50-51.
44. Lange-Asschrnfeldt, B., Velasco, P., Streit, P. et al. (2001). The angiogenesis inhibitor vasoslatin does not impair wound healing at tumor inhibiting doses. Journal of Investigative Dermatology 117, 1036-1041.
45. LANGER, R. and Vacanti, J.P. (1993). Tissue engineering. Science 260,920-923.
46. LANZA, R.P., HAYES, J.L. and CHICK, W.L. (1996). Encapsulated cell technology. Nature Biotechnology 14, 1107-1111.
47. LEE, B.M., MacDonald, NJ. and Gubish, E.R. (2000). Angiostatin and endostatin: endogenous inhibitors of tumor growth. Cancer and Metastasis Reviews 19, 181-390.
48. LIM, F. and SUN, A.M. (1980). Microencapsulated islets bioartificial endocrine pancreas. Scientific American 210,908-910.
49. Lin, P., Buxton, J.A., Acheson, A. et al. (1998). Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proceedings of the National Academy of Sciences of the United States of America 95, 8829-8834.
50. Lindner, M.D., Plone, M. A., Mullins, T.D. et al. (1997). Somatic delivery of catecholamines in the striatum attenuate parkinsonian symptoms and widen the therapeutic window of oral sinemet in rats. Experimental Neurology 145, 130-140.
51. Liu, F. and HUANG, L. (2002). Development of non-viral vectors for systemic gene delivery. Journal of Controlled Release 78, 259-266.
52. Lu, D., Jimenez, X., Zhang, H. et al. (2001). Complete inhibition of vascular endothelial growth factor activities with a functional antibody directed against both VEGF kinase receptor, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Research 61, 7002-7008.
53. Luca, M., Huang, S., Gershenwald, J.E. et al. (1997). Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. American Journal of Pathology 151, 1105-1113.
54. Maione, T.E., Gray, G.S., Petro, J. et al. (1990). Inhibition of angiogenesis by recombinant human platelet-4 and related peptides. Science 247,77-90.
55. MEYER, F. and FINER, M. (2001). Gene therapy: progress and challenges. Cellular and Molecular Biology 47, 1277-1294.
56. MULLIGAN, R.C. (1993). The basic science of gene therapy. Science 260, 926-932.
57. Murray, G.I., Duncan, M.E., O’Neil, P. et al. (1996). Matrix metalloproteinase-l is associated with poor prognosis in colorectal cancer. Nature Medicine 2,461-462.
58. NABEL, G.J., NABEL, E.G. and YANG, Z.Y. (1993). Direct gene transfer with DNA-liposome complexes in melanoma: expression, biological activity and lack of toxicity in human. Proceedings of the National Academy of Sciences of the United States of America 90, 11307-11311.
59. O’Reilly, M.S., Holmgren, L., Shing, Y. et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
60. O’Reilly, M.S., Boehm, T., Shing, Y. et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88,277-285.
61. ORIVE, G., Hernandes, R.M., Gascon, A.R. et al. (2001). Microencapsulation of an anti-VE-cadherin antibody secreting 1B5 hybridoma cells. Biotechnology and Bioengineering 76, 285-290.
62. PALLINI, R., CONSALES, A., Lauretti, L. and FERNANDEZ, L.E. (1997). Experiments in a Parkinson’s rat model [letter; comment]. Science 277, 389-390.
63. PARKASH, S. and CHANG, T.M.S. (1996). Microencapsulated genetically engineered live E. colt DH5 cells administered orally to maintain normal plasma urea level in uramic rats. Nature Medicine 2, 883-887.
64. Patrick, C.W., Zheng, B., Wu, X. et al. (2001). Muristerone A-induced nerve growth factor release from genetically engineered human dermal Fibroblasts for peripheral nerve tissue engineering. Tissue Engineering 7, 303-311.
65. PEIRONE, M.A., DELANEY, K., KWIECIN, J. and FLETCH, P.L.A. (1998). Delivery ofrecombinant gene product to canines of neurons in the substantia nigra in vivo, with non-autologous microencapsulated cells. Human Gene Therapy 9, 195-206.
66. PEROULIS, I., JONAS, N. and SALEH, M. (2002). Antiangiogenic activity of endostatin inhibits C6 glioma growth. International Journal of Cancer 97, 839-845.
67. Puumalainen, A.M., Vapalahti, M., Agrawal, R.S. et al. (1998). Beta-gaiactosidasegene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. Human Gene Therapy 9,1769-1774.
68. Read, T.A., Sorensen, D.R., Mahesparan, R. et al. (2001), Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nature Biotechnology 19,2934.
69. Reguljer, E., Pau, S., Mariglsano, M. et al. (2001). Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach. Cancer Gene Therapy 8,45-54.
70. RINSCH, C., Regulier, E., DEGLON, N. et al. (1997). A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension. Human Gene Therapy 8,1881-1889.
71. SAUTER, B.V., Martinet, O., Zhang, WJ. et al. (2000). Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proceedings of the National Academy of Sciences of the United States of America 97, 4802-4807.
72. SAVELKOUL, H.F., VAN OMMEN, R., Vossen, A.C. et al. (1994). Modulation of systemic cytokine levels by implantation of alginate encapsulated cells. Journal of Immunological Methods 170, 185-196.
73. SCHUCH, G., MACHLUF, M., BARTSCH, G. et al. (2002). In vivo administration of VEGF and its antagonist, soluble neuropilin-l (sNRPl), predicts a role of VEGF in progression of acute myeloid leukemia in vivo. Blood 100, 4622-4628.
74. Shapiro, L. and Cohen, S. (1997). Novel alginate sponges for cell culture and transplantation. Biomaterials 18, 583-590.
75. SHOFENG, Y., KAHFAI, L., JHAOUI, D. and CHEE-KAI, D. (2001). The design of scaffolds for use in tissue engineering. Part I. Traditional factors. Tissue Engineering 7, 679-689.
76. Siebers, U., Horcher, A., Brandhorst, D. et al. (1998). Time course of the cellular reaction toward microencapsulated xenogenic islets in the rat. Transplantation Proceedings 30, 494-495.
77. SNYDER, R.O., MIAO, C.H. and PATUN, G.A. (1997). Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nature Genetics 16, 270-276.
78. Soon-Shiong, P., Feldman, E., Nelson, R. et al. (1993). Long term reversal of diabetes by the injection of immunoprotected islets. Proceedings of the National Academy ofSciences of the United States of America 90, 5843-5847.
79. STEARNS, M.E., RHIM, J. and WANG, M. (1999). Interleukin 10 inhibition of primary human prostate cell-induced angiogenesis: IL-10 stimulation of tissue inhibitor of metalloproteinase-1 and inhibition of matrix metalloproteinase(MMP)-2/MMP-9 secretion. Clinical Cancer Research 5, 189-196.
80. Strawn, L.M., McMahon, G., App, H. et al. (1996). Flk-1 as a target for tumor growth inhibition. Cancer Research 56, 3540-3545.
81. SZARY, J. and SZALA, S. (2001). Intra-tumoral administration of naked plasmid DN A encoding mouse endostatin inhibits renal carcinoma growth. International Journal of Cancer 91, 835-839.
82. TEMIN, H.M. (1990). Safety considerations in somatic gene therapy of human disease with retrovirus vectors. Human Gene Therapy 1, 111-123.
83. Thorsen, F., Read, T. A., Lung-Johansen, M. et al. (2000). Alginate-encapsulated producer cells: a potential new approach for the treatment of malignant brain tumors. Cell Transplant 9,773-783.
84. TRESCO, P.A. (1994). Encapsulated cells for sustained neurotransmitter delivery to the central nervous system. Journal of Controlled Release 28, 253-258.
85. van Hinsbergh, V.W.M., Collen, A., Koolwijk, P. et al. (1999). Angiogenesis and antiangiogenesis: perspectives for the treatment of solid tumors. Annals of Oncology 10, 560-563.
86. Weber, C.J., Zabinski, S., Kosshitzky, T. et al. (1990). The role of CD34 helperT ceils in destruction of microencapsulated cells. Transplantation 49, 396-404.
87. WEINBERG, S.R. and STOHLMAN, F., JR. (1976). Growth of mouse yolk sac cells cultured in vivo. British Journal of Haematology 32,543-555.
88. Winn, S.R., Hammang, J.P., Emerich, D.F. et al. (1994). Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons. Proceedings of the National Academy of Sciences of the United States of America 91, 2324-2328.
89. Xiao, F., Wei, Y., Yang, L. et al. (2002). A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Therapy 18, 1207-1213.
90. Yamaguchi, T.P., Anand, A.B., Lee, M. et al. (1999). Endostatin inhibits VEGF induced endothelial cell migration and tumor growth independently of zinc binding. EMBO Journal 18, 4414-4423.
91. Yla-Herttuala, S. and Martin, J.F. (2000). Cardiovascular gene therapy. Lancet 355,213-222.